Expression of Epstein-Barr Virus-Encoded Latent Membrane Protein 1 in Nonendemic Burkitt's Lymphomas
To the Editor: A restricted form of Epstein-Barr virus (EBV)-latent infection (latency I), has been consistently observed in Burkitt's lymphoma (BL) cell lines and fresh BL biopsy specimens.'.2 This pattern of EBV latency is characterized by selective expression of EBV-encoded nuclear antigen (EBNA) 1 (together with two noncoding small RNAs-EBERs). The first demonstration of forms of EBV latency other than latency I in endemic BL has recently been provided by Niedobitek et a1; who found unexpected heterogeneity in the latent gene phenotype of EBV+ BL biopsy specimens. Using sensitive immunohistologic techniques, expression of latent membrane protein (LMP) I was detected in a proportion of tumor cells in two cases and EBNA 2 was observed in some tumor cells in three other cases. LMP 1 expression was not detected in those cases displaying EBNA 2. In the remaining endemic BL cases EBV latent gene expression was restricted to the EBERs (latency I). These data conclusively show that EBV-infected tumor cells of endemic BL may sustain three distinct forms of viral latency. It is interesting to note in this context that the expression of LMP l, in the absence of EBNA 2, has already been observed in a limited number of EBV' acquired immunodeficiency syndrome (AIDS)-related BL In 3 of the 10 EBV' AIDS-related BL and in 2 of the 6 EBV+ AIDS-unrelated BL cases, small numbers (<l%) of focally distributed tumor cells were found to express LMP 1 (Fig l) , but not EBNA 2 (Table l) , suggesting a latency II phenotype. LMP 1 expression was observed in both tumor cells with classic BL cell morphology or with immunoblastic-like morphology (enlarged nuclei with prominent nucleoli). The remaining EBV+ BL cases consisted exclusively of tumor cells showing an EBV phenotype apparently corresponding to a latency I pattern. LMP l + and LMP 1-BL cases were histologically indistinguishable. Expression of BCL-2 oncoprotein or CD30 in small numbers of tumor cells was observed in 4 of 5 and 1 of 5 LMP l + cases, respectively ( Table l) . Double immunostaining showed BCL-2 (but not CD30) coexpression in a fraction of LMP 1 -expressing cells (Fig 2) . In all tested cases BCL-2 expression was also observed in reactive small lymphoid cells.
Our study, which confirms LMP 1 expression in a fraction of EBV+ AIDS-related BL cases, also provides the first demonstration of a form of EBV latency other than latency I in a proportion of tumor cells of nonendemic AIDS-unrelated BL cases. These data, in 
